
About Mycovia Pharmaceuticals
Mycovia Pharmaceuticals is a Healthcare company based in Durham (United States) founded in 2018. Small molecule therapeutics are developed for recurrent vulvovaginal candidiasis treatment. Mycovia Pharmaceuticals offers products and services including VIVJOA. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Fungal. Its competitors include Scynexis, Amplyx Pharmaceuticals and Elion Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2018 and based in Durham, United States, Mycovia Pharmaceuticals operates in the biopharmaceutical sector. Small molecule-based therapeutics are developed by the company to address recurrent vulvovaginal candidiasis in women. The lead candidate, VT-1161, targets fungal cytochrome P450 sterol 14α-demethylase and has advanced through Phase 2b clinical trials. Focus remains on innovative antifungal treatments within this specialized field.
- Headquarters Durham, United States
- SectorsHealthcare
- Email••••••••
- Website mycovia.com
- Social LinkedIn X
- Latest Funding Round$710K (USD), Grant
Jun 2018
- Investors
Products & Services of Mycovia Pharmaceuticals
Mycovia Pharmaceuticals offers a comprehensive portfolio of products and services, including VIVJOA.
Capsules used for treating fungal infections in patients.
Funding Insights of Mycovia Pharmaceuticals
- Total Rounds 1
- Last Round Grant — $710,000
- First Round $710,000
(Jun 2018)
- Investors Count 1
All 1 funding rounds of Mycovia Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2018 | $710,000 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Mycovia Pharmaceuticals
Mycovia Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Mycovia Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Mycovia Pharmaceuticals
11 people are tracked at Mycovia Pharmaceuticals (9 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Rachel Gee | VP, Project Management and Regulatory Affairs | Leadership |
Stephen Brand | Chief Development Officer | Leadership |
Patrick Jordan | CEO | Leadership |
Kristen Oberg | VP, Operations | Leadership |
Thorsten Degenhardt | Chief Operating Officer | Leadership |
Susan McGaurn | Senior Director, Medical Affairs | Leadership |
Janelle Branoff Ms, Pmp, Ca-Am | Director, Program And Alliance Management | Leadership |
Mark Coffin | Senior Director Pharmaceutical Development | Leadership |
Stacey Curelop | Director Of Clinical Operations | Leadership |
Shawana Taylor M.d. | Senior Medical Science Liaison | Team |
Miranda Sheldon | Finance Manager | Team |
Complete people profiles for Mycovia Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Mycovia Pharmaceuticals
2 dated milestones of Mycovia Pharmaceuticals, from founding to its latest funding, stage changes and deals.
- Founded Mycovia Pharmaceuticals is founded.
- Funding First funding round of $710K.
Competitors of Mycovia Pharmaceuticals
Mycovia Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Scynexis, Amplyx Pharmaceuticals and Elion Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| scynexis.com | 1999 | Jersey, United States | $62.65M | 50 | Developing glucan synthase inhibitors for the treatment of fungal infections. | |
| amplyx.com | 2006 | San Diego, United States | $144.31M | 15 | Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma. | |
| eliontx.com | 2024 | New York, United States | $81M | Therapeutics for invasive fungal infections are developed by Elion Therapeutics. |
Detailed competitors of Mycovia Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Mycovia Pharmaceuticals (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 87.11 M | 4,647 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mycovia Pharmaceuticals
Complete news archive for Mycovia Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mycovia Pharmaceuticals
Mycovia Pharmaceuticals was founded in 2018.
Mycovia Pharmaceuticals is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Founded in 2018 and based in Durham, United States, Mycovia Pharmaceuticals operates in the biopharmaceutical sector. Small molecule-based therapeutics are developed by the company to address recurrent vulvovaginal candidiasis in women. The lead candidate, VT-1161, targets fungal cytochrome P450 sterol 14α-demethylase and has advanced through Phase 2b clinical trials. Focus remains on innovative antifungal treatments within this specialized field.
Mycovia Pharmaceuticals's top competitors include Scynexis, Amplyx Pharmaceuticals and Elion Therapeutics.
Mycovia Pharmaceuticals offers VIVJOA.
Mycovia Pharmaceuticals has 1 investor. Key investors include HHS.
